Neurology · MigraineRegulatory Approvalcommercialmid-term

FDA Submission for Ubrogepant by Zydus Pharmaceuticals

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Zydus Pharmaceuticals9 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/16/2026, 6:31:41 PM

Assessment confidence: 57% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of an ANDA for Ubrogepant by Zydus Pharmaceuticals signals a potential increase in competition within the migraine treatment market. This could impact pricing and market share for existing branded formulations, necessitating strategic adjustments. Regulatory context from FDA (FDA TA — UBROGEPANT (ORIG)) supports the near-term read. Assessment grounded in 17 ranked evidence items (4 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of a potential generic Ubrogepant on market share and pricing strategies. The strongest clinical anchor is Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata (ClinicalTrials.gov), sponsor/company relevance (novartis). In Neurology · Migraine, 3 regulatory and 3 competitive items passed relevance filtering for Zydus Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Grants Priority Review for LEQEMBI Supplement Application. The submission may increase competition in the migraine treatment space, particularly against existing branded formulations of Ubrogepant.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — UBROGEPANT (ORIG) (FDA). Entity match (zydus pharmaceuticals); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The FDA's review and potential approval of the ANDA will be crucial in determining the timeline for generic entry and its implications for compliance and market dynamics.

Key Risks

Elevated medium regulatory exposure for Zydus Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of a generic Ubrogepant could lead to price erosion and loss of market share for current branded products, affecting revenue streams.
Upside for Zydus Pharmaceuticals may improve if First Evaluation of Craniofacial Nerve Stimulation System in Chronic Migraine (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of a potential generic Ubrogepant on market share and pricing strategies.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any subsequent approval announcements for ANDA218662.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — UBROGEPANT (ORIG)
FDAhigh relevance
Entity match (zydus pharmaceuticals); Regulatory pathway relevance (nda)
FDA document
View source
FDA’s Drug Registration and Listing Workshop: Compliance, Regulatory and Submission Updates - 09/29/2026
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Register to make submissions to the MHRA
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
First Evaluation of Craniofacial Nerve Stimulation System in Chronic Migraine
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
E-cigarette Social Media Marketing and Its Perceptions by Youth
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Grants Priority Review for LEQEMBI Supplement Application
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves First At-home Starting Dose for Leqembi in Alzheimer's Treatment
Humanexa Signalsmedium relevance
Moderate corpus alignment

Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Adaption of a posttraumatic stress disorder intervention for patients who use stimulants and opioids in the opioid treatment programme setting.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluation of nirmatrelvir/ritonavir treatment for COVID-19 on health-related outcomes: a global economic value systematic literature review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Zydus Pharmaceuticals
Ubrogepant
migraine treatment market

Commercial impact

medium

The entry of a generic Ubrogepant could lead to price erosion and loss of market share for current branded products, affecting revenue streams.

Regulatory impact

medium

The FDA's review and potential approval of the ANDA will be crucial in determining the timeline for generic entry and its implications for compliance and market dynamics.

What to watch

Monitor the FDA's review timeline and any subsequent approval announcements for ANDA218662.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.